Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
1995-2-27
|
pubmed:abstractText |
We studied a 45-69 lipopeptide obtained by N-terminal modification with a N epsilon-palmitoyl lysine residue of the 45-69 peptide derived from the nef protein of HIV. T cells from animals immunized intraperitoneally with 45-69 lipopeptide proliferated in vitro in the presence of 45-69 peptide while no response was obtained after intraperitoneal immunization with 45-69 peptide. The efficiency of the 45-69 lipopeptide is supported by the covalent association to the N epsilon-palmitoyl lysine moiety. The immunogenicity of the 45-69 lipopeptide or of the unmodified peptide is dependent on the route of immunization but is not related to a mitogenic effect on cells or to an increase of the peptide antigenicity. Moreover, only 45-69 lipopeptide induces the secretion of cytokines such as IL-1, IL-6 and TNF-alpha by peritoneal macrophages. Finally, the use of 45-69 lipopeptide permits the activation of highly purified T cells without the addition of antigen-presenting cells. These results have implications for the formulation of synthetic vaccines.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Gene Products, nef,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/nef Gene Products, Human...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0264-410X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1209-14
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7839726-Amino Acid Sequence,
pubmed-meshheading:7839726-Animals,
pubmed-meshheading:7839726-Antigen Presentation,
pubmed-meshheading:7839726-Cytokines,
pubmed-meshheading:7839726-Gene Products, nef,
pubmed-meshheading:7839726-HIV-1,
pubmed-meshheading:7839726-Immunization,
pubmed-meshheading:7839726-Injections, Intraperitoneal,
pubmed-meshheading:7839726-Injections, Subcutaneous,
pubmed-meshheading:7839726-Lipoproteins,
pubmed-meshheading:7839726-Macrophage Activation,
pubmed-meshheading:7839726-Male,
pubmed-meshheading:7839726-Molecular Sequence Data,
pubmed-meshheading:7839726-Molecular Structure,
pubmed-meshheading:7839726-Rats,
pubmed-meshheading:7839726-Rats, Inbred Lew,
pubmed-meshheading:7839726-T-Lymphocytes,
pubmed-meshheading:7839726-Vaccines, Synthetic,
pubmed-meshheading:7839726-nef Gene Products, Human Immunodeficiency Virus
|
pubmed:year |
1994
|
pubmed:articleTitle |
Effect of a lipopeptidic formulation on macrophage activation and peptide presentation to T cells.
|
pubmed:affiliation |
Centre d'Immunologie des Maladies Transmissibles et Allergiques, Unité mixte INSERM U167-CNRS 624, Lille, France.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|